An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
MacroGenics to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
MacroGenics, Inc. (Nasdaq: MGNX) announced its participation in upcoming investor conferences: BMO Biopharma Spotlight Series: Oncology Day on November 8, Stifel 2023 Healthcare Conference on November 14, and 6th Annual Evercore ISI HealthCONx Conference on November 28. Webcasts of the presentations will be available on the company's website.
Positive
None.
Negative
None.
ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences:
BMO Biopharma Spotlight Series: Oncology Day Date: Wednesday, November 8, 2023 Fireside Chat: 10:30 am ET Location: Virtual
Stifel 2023 Healthcare Conference Date: Tuesday, November 14, 2023 Fireside Chat: 3:00 pm ET Location: New York
6th Annual Evercore ISI HealthCONx Conference Date: Tuesday, November 28, 2023 Fireside Chat: 7:55 am ET Location: Miami
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
FAQ
What is the company name mentioned in the press release?
The company mentioned in the press release is MacroGenics, Inc.
What is the stock symbol of MacroGenics, Inc.?
The stock symbol of MacroGenics, Inc. is MGNX.
What conferences is MacroGenics participating in?
MacroGenics is participating in the BMO Biopharma Spotlight Series: Oncology Day on November 8, Stifel 2023 Healthcare Conference on November 14, and 6th Annual Evercore ISI HealthCONx Conference on November 28.
Where can I access webcasts of the presentations?
Webcasts of the presentations can be accessed on MacroGenics' website under the 'Events & Presentations' section.
How long will the webcast replays be available?
The company will maintain archived replays of the webcasts on its website for 30 days.
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!